The North America Point of Care (PoC) Diagnostics market is experiencing robust growth, driven by technological advancements and increasing demand for rapid diagnostic solutions. The market size was valued at USD 7,950 Million in 2025 and is projected to reach USD 19,320 Million by 2035, growing at a CAGR of 8.4% from 2024 to 2035. Increasing prevalence of chronic diseases, coupled with the need for decentralized, patient-centric healthcare models, is fueling demand for PoC diagnostics across North America.
The economic impact of tariffs on "North America Point of Care Diagnostics Market".
Market Growth Drivers
Rising Prevalence of Chronic and Infectious Diseases: The increasing incidence of chronic diseases such as diabetes, cardiovascular disorders, and infectious diseases in North America is propelling the demand for rapid and accurate point-of-care diagnostic solutions. Companies like Abbott Laboratories have introduced portable glucometers and rapid influenza diagnostic tests, enhancing the accessibility and reliability of diagnostic processes at the patient’s bedside or in remote settings. The COVID-19 pandemic has further accelerated the adoption of PoC diagnostics, emphasizing the need for quick, accurate, and easy-to-use devices in early disease detection and management.
Technological Advancements and Product Innovation: Continuous advancements in diagnostic technologies, including miniaturized biosensors, microfluidics, and connectivity features for integrated data management, are transforming the PoC diagnostics landscape. For instance, Roche Diagnostics has launched several next-generation PoC devices with improved sensitivity, multiplexing capabilities, and scalable platforms that meet the growing needs of healthcare providers. The integration of AI and cloud connectivity in PoC diagnostics is expected to further create efficiencies and minimize diagnostic errors, attracting more adoption across North America.
Market Trends
Growing Adoption of Telehealth and Remote Patient Monitoring: The convergence of telehealth services with point of care diagnostics is gaining momentum in North America. Companies like BD (Becton Dickinson) are deploying cloud-enabled diagnostic devices that provide real-time results directly to healthcare providers and patients. This trend is revolutionizing disease management, particularly for patients in rural or underserved regions, and is expected to expand further as digital health infrastructure advances.
Increasing Partnerships between Diagnostic Companies and Pharmacies: Major players such as QuidelOrtho and CVS Health have entered into strategic partnerships to provide PoC diagnostic testing at retail pharmacy locations across the United States. This trend allows broader community access to diagnostic services, particularly for infectious diseases, and supports public health initiatives to control disease spread through quick detection and response. Such collaborations are expected to further drive market expansion and innovation.
Market Opportunity
Expansion of Testing Capabilities Beyond Traditional Healthcare Settings: There is a rising opportunity for companies like Abbott and bioMérieux to develop PoC diagnostic solutions tailored for use in non-traditional settings such as workplaces, schools, and pharmacies. This expansion can lead to increased adoption rates and accessibility, especially for population screening and chronic disease management in North America.
Personalized Medicine and Companion Diagnostics: The integration of PoC diagnostics with personalized medicine approaches and companion diagnostics presents a significant opportunity. Companies developing rapid genetic or biomarker-based PoC tests can support targeted therapy decisions, improving treatment outcomes and driving market differentiation.
North America Point of Care Diagnostics Market Revenue (USD Million), 2020-2035
The chart demonstrates consistent and accelerating growth in the market revenue for North America Point of Care Diagnostics from 2020 to 2035. In 2020, the market revenue stood at approximately USD 4,880 Million, driven by rising chronic disease incidence and the COVID-19 pandemic’s impact on rapid testing. Market revenue rose steadily, reaching an estimated USD 7,950 Million by 2025. From 2025 onward, the market shows robust expansion, propelled by technological advances and shifting healthcare delivery models. Revenue is projected to reach USD 19,320 Million by 2035, reflecting an overall CAGR of 8.4% during the period. This sustained growth highlights the increasing significance and integration of point of care diagnostics throughout the North American healthcare ecosystem.
North America Point of Care Diagnostics Market by Region Share (%), 2025
The pie chart illustrates market share by region within North America for 2025. The United States dominates the market, accounting for 72% of the regional market share, a reflection of its advanced healthcare infrastructure, higher investment in PoC technologies, and wide adoption in both clinical and retail settings. Canada follows with a 18% share due to strong healthcare access and increasing investments in rapid diagnostics. Mexico contributes 7%, benefiting from growing healthcare modernization and government initiatives. Other regions, including Puerto Rico and other Caribbean islands, collectively contribute the remaining 3%. This regional distribution underscores the dominance of the U.S. market while also highlighting growth potential in neighboring countries.
Recent Developments
In April 2024, Abbott Laboratories announced the launch of the ID NOW™ RSV assay in North America, extending its molecular point of care testing portfolio for respiratory illnesses. The ID NOW platform provides rapid, accurate detection of respiratory syncytial virus (RSV) in under 15 minutes, supporting both pediatric and adult patient populations in clinical and urgent care settings.
In May 2024, Roche Diagnostics received FDA Emergency Use Authorization for its latest SARS-CoV-2 and Influenza A/B combo point of care test, which enables simultaneous detection of multiple respiratory pathogens with high sensitivity. This development is expected to enhance syndromic testing capabilities for hospitals and clinics as respiratory virus season approaches.
In June 2024, QuidelOrtho expanded its partnership with Walgreens, increasing the availability of its Sofia 2 Flu + SARS Antigen tests to over 8,000 pharmacy locations across North America. This collaboration aims to provide broader, community-based access to fast diagnostic testing, supporting effective outbreak management and improving patient convenience.
Press Releases